Phase I-II study of radiolabeled antibody integrated in the treatment of primary hepatic malignancies

Stanley E. Order, Jerry L. Klein, David Ettinger, Philip Alderson, Stanley Siegelman, Peter Leichner

Research output: Contribution to journalArticlepeer-review

Abstract

Primary intrahepatic malignancies have been demonstrated to contain tumor associated antigens which bind radiolabelled anti-CEA and anti-ferritin antibodies. The present study reports the toxicity and possible therapeutic efficacy of radiolabelled antibodies that were administered at 50 and 100 millicurie doses following combination radiation and chemotherapy. Three of 10 patients who entered into the study completed therapy on schedule and have had remissions of 7, 9, and 18 months; 2 of the 3 patients were alive at 1 and 2 years after treatment. Of 5 patients who were administered radioimmunoglobulin, the singular toxicity was 3 weeks of marrow hypoplasia in one patient who susequently recovered. The remaining 5 patients were at various stages of protocol treatment prior to immunoglobulin treatment. Eight of the 10 patients have had computer analysis of sequential computerized axial tomography (CAT) scans obtained during the course of therapy and at follow up examination. No major organ toxicity was noted. Clinical remissions were documented by computer analysis of the CAT scans to determine the percent of residual tumor.

Original languageEnglish (US)
Pages (from-to)703-710
Number of pages8
JournalInternational journal of radiation oncology, biology, physics
Volume6
Issue number6
DOIs
StatePublished - Jun 1980

Keywords

  • 1311 antibody
  • Hepatoma
  • Phase I-II

ASJC Scopus subject areas

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Fingerprint

Dive into the research topics of 'Phase I-II study of radiolabeled antibody integrated in the treatment of primary hepatic malignancies'. Together they form a unique fingerprint.

Cite this